The stock of GenMark Diagnostics, Inc (NASDAQ:GNMK) is a huge mover today! About 85,136 shares traded hands. GenMark Diagnostics, Inc (NASDAQ:GNMK) has risen 107.20% since March 7, 2016 and is uptrending. It has outperformed by 99.61% the S&P500.
The move comes after 5 months positive chart setup for the $568.36M company. It was reported on Oct, 10 by Barchart.com. We have $21.50 PT which if reached, will make NASDAQ:GNMK worth $358.07M more.
Analysts await GenMark Diagnostics, Inc (NASDAQ:GNMK) to report earnings on October, 25. They expect $-0.31 EPS, down 14.81% or $0.04 from last year’s $-0.27 per share. After $-0.30 actual EPS reported by GenMark Diagnostics, Inc for the previous quarter, Wall Street now forecasts 3.33% negative EPS growth.
GenMark Diagnostics, Inc (NASDAQ:GNMK) Ratings Coverage
Out of 3 analysts covering Genmark Diagnostics (NASDAQ:GNMK), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Genmark Diagnostics has been the topic of 5 analyst reports since October 14, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating by Needham given on Wednesday, February 24. On Friday, September 16 the stock rating was upgraded by Cowen & Co to “Outperform”. Needham maintained GenMark Diagnostics, Inc (NASDAQ:GNMK) rating on Wednesday, October 28. Needham has “Buy” rating and $13 price target.
According to Zacks Investment Research, “GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensorÂ® XT-8 system is the second generation in GenMark Dx’s eSensorÂ® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual’s ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual’s increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California.”
Insitutional Activity: The institutional sentiment decreased to 0.91 in 2016 Q2. Its down 0.50, from 1.41 in 2016Q1. The ratio fall, as 11 funds sold all GenMark Diagnostics, Inc shares owned while 23 reduced positions. 3 funds bought stakes while 28 increased positions. They now own 43.35 million shares or 1.06% less from 43.82 million shares in 2016Q1.
Tiaa Cref Limited Liability Corporation owns 167,060 shares or 0% of their US portfolio. Turner Invests Lp has invested 0.07% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK). Victory Cap Inc holds 0% or 5,578 shares in its portfolio. Artisan Prtnrs Lp last reported 0.04% of its portfolio in the stock. California State Teachers Retirement has 84,174 shares for 0% of their US portfolio. Moreover, Ig Invest has 0% invested in GenMark Diagnostics, Inc (NASDAQ:GNMK) for 141,280 shares. Nationwide Fund Advsrs has 0% invested in the company for 26,112 shares. The Illinois-based Alyeska Inv Group L P has invested 0.03% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Fmr Ltd Company has 6.42 million shares for 0.01% of their US portfolio. The New York-based Jpmorgan Chase & has invested 0.01% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Citigroup accumulated 0% or 1,483 shares. Schwab Charles Invest Management accumulated 0% or 149,145 shares. The North Carolina-based Bank & Trust Of America Corporation De has invested 0% in GenMark Diagnostics, Inc (NASDAQ:GNMK). Weiss Multi last reported 0.05% of its portfolio in the stock. Great West Life Assurance Can has invested 0% of its portfolio in GenMark Diagnostics, Inc (NASDAQ:GNMK).
Insider Transactions: Since May 9, 2016, the stock had 1 buy, and 24 sales for $416,178 net activity. Another trade for 5,608 shares valued at $51,627 was made by Williams Jennifer Anne on Wednesday, August 17. 523 shares were sold by Gleeson Michael, worth $4,545. Kayyem Jon Faiz sold $1,334 worth of GenMark Diagnostics, Inc (NASDAQ:GNMK) on Tuesday, August 2. The insider Giles Lisa M. bought 823 shares worth $7,736. Chakravarty Ingo had sold 582 shares worth $3,154 on Monday, May 9. MASSARANY HANY had sold 1,186 shares worth $10,306. Stier Eric sold $4,467 worth of stock or 512 shares.
More recent GenMark Diagnostics, Inc (NASDAQ:GNMK) news were published by: Fool.com which released: “Why GenMark Diagnostics, Inc. Is Soaring Today” on September 16, 2016. Also Quotes.Wsj.com published the news titled: “News GenMark Diagnostics Inc.GNMK” on February 11, 2011. Seekingalpha.com‘s news article titled: “GenMark Diagnostics Is A Worthy Fourth-Quarter Buying Opportunity” with publication date: August 26, 2016 was also an interesting one.
GNMK Company Profile
GenMark Diagnostics, Inc. (GenMark), incorporated on February 12, 2010, is a molecular diagnostics company. The Firm focuses on developing and commercializing its eSensor detection technology. The Company’s eSensor electrochemical technology enables detection of multiple distinct biomarkers in a single sample. The Firm sells its XT-8 instrument and related diagnostic and research tests (XT-8 system) in the United States. In addition, it has developed and intends to commercially launch its sample-to-answer ePlex instrument and its associated diagnostic tests, which it collectively refers to as its ePlex system, in Europe and the United States. It operates in the development, manufacturing, sales and support of instruments and molecular tests based on its eSensor detection technology segment. The Company’s XT-8 system received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular research and diagnostic tests with a workstation and disposable test cartridges. The Company’s XT-8 system supports approximately 20 independent test cartridges. It has an installed base of over 630 XT-8 analyzers, or placements, with its customers. It has a menu of approximately eight tests for use with its XT-8 system. Approximately four of its diagnostic tests, which run on its XT-8 instrument, have received United States Food and Drug Administration clearance, including Cystic Fibrosis Genotyping Test, Warfarin Sensitivity Test, Thrombophilia Risk Test and Respiratory Viral Panel.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.